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Introduction
• ddPCR, or Digital Drop PCR, is a relatively recent technology (2011) and 
method for digital PCR
• Like qPCR, ddPCR can be used to determine the Vector Copy Number 
(VCN) of gene modified cell therapy products1
• Benzonase is a product that removes excess nucleic acids from transduced 
cells3
• This project aims to explore the use of ddPCR for determination of the VCN 
for cell therapy products and whether Benzonase treatment is necessary 
before DNA extraction and ddPCR
Digital Droplet PCR (ddPCR)
Benzonase
• Genetically engineered product form Serratia marcescens that hydrolyzes 
nucleic acids
• Degrades nucleic acids to 5’-monophosphate terminated oligonucleotides (2-
5 bases) and requires Mg2+ and Ca2+ for activity 
• Removes the residual DNA during virus production
• Current cells samples are shared with VCN and RCR. RCR samples need to 
be treated by Benzonase, so the VCN cell samples are also treated with 
Benzonase. 
• A search of published literature on VCN assay found that samples were not 
Benzonase treated3

































Figure 2: Method for Non Benzonase vs. Benzonase Treatment & RPP30 vs. RNase P Reference
Vector Copy Number (VCN)
• The FDA recommends that the VCN should be less than 5 copies per genome 
in gene modified cell therapy products 
•The vector is integrated into the genomic DNA
•Increased risk of oncogenesis when VCN is high 




• Benzonase treatment reduced RNase P concentration in the final ddPCR 
products but did not affect Gene of Interest-1 and RPP30.  
• Benzonase treatment did not affect DNA of Interest-2 VCN with RPP30 as a 
reference but did affect Gene of Interest-1 VCN with RPP30. 
• Residual Benzonase or Impurity of the Product affected RNase P PCR Product
• Based on the results, the fact that Benzonase treatment is not a requirement 
for VCN samples, and published literature of VCN samples not treated with 
Benzonase, it is suggested that Benzonase treatment should not be included 
in VCN sample preparation. 
Figure 5: Benzonase Treatment with RNase P & RPP30 Reference Genes (using Gene of Interest 2)
Figure 6: Comparison of different wash times after Benzonase Treatments
















Two-dimensional scatter plot for Gene of Interest - 1 
VCN data analysis
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